MarketScreener Homepage > Equities > Nasdaq > Inovio Pharmaceuticals, Inc. INO

Report

Delayed Nasdaq - 12/01 04:00:00 pm
12.42	USD		+1.64%

11/25

EXPLAINER : When and how will COVID-19 vaccines become available?

11/23

INOVIO PHARMACEUTICALS : Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)

11/20

INOVIO PHARMACEUTICALS : Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

11/24/2020	11/25/2020	11/27/2020	11/30/2020	12/01/2020	Date
10.15(c)	10.39(c)	12.26(c)	12.22(c)	12.42(c)	Last
9 927 550	11 057 299	21 178 705	23 173 490	20 151 126	Volume
-2.22%	+2.36%	+18.00%	-0.33%	+1.64%	Change

More quotes

Financials (USD)

Sales 2020	4,06 M - -
Net income 2020	-181 M - -
Net Debt 2020	- - -
P/E ratio 2020	-10,4x
Yield 2020	-

Sales 2021	143 M - -
Net income 2021	-156 M - -
Net Debt 2021	- - -
P/E ratio 2021	-13,7x
Yield 2021	-

Capitalization	2 070 M 2 070 M -
Capi. / Sales 2020	510x
Capi. / Sales 2021	14,5x
Nbr of Employees	190
Free-Float	97,8%

More Financials

Company

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target...

Sector

Biotechnology & Medical Research

Calendar

03/17

Ergebnisveröffentlichung

More about the company

Notations Surperformance© of Inovio Pharmaceuticals, Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about INOVIO PHARMACEUTICALS, INC.

11/25	EXPLAINER : When and how will COVID-19 vaccines become available?	RE
11/23	INOVIO PHARMACEUTICALS : Announces Dosing of First Subject in Phase 1/2 Clinical..	PR
11/20	INOVIO PHARMACEUTICALS : Presents Clinical Results of its DNA Medicines INO-5401..	PR
11/18	PFIZER, MODERNA COVID-19 VACCINES MA : U.S. official	RE
11/16	INOVIO PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (..	AQ
11/16	INOVIO PHARMACEUTICALS : to begin mid-stage study of COVID-19 vaccine candidate	RE
11/16	INOVIO PHARMACEUTICALS : to begin mid-stage study of COVID-19 vaccine candidate	RE
11/16	INOVIO PHARMACEUTICALS : Announces Initiation of Phase 2 Segment of its Phase 2/..	PR
11/10	Arcturus expects its COVID-19 vaccine to be ready by Q1 2021	RE
11/09	GRAPHIC : Tracking the vaccine race	RE
11/09	INOVIO : 3Q Earnings Snapshot	AQ
11/09	INOVIO PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results	PR
11/09	INOVIO PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..	AQ
11/02	CEPI to fund development of COVID-19 vaccine candidate by China's Clover	RE
10/26	INOVIO PHARMACEUTICALS : to Report Third Quarter 2020 Financial Results on Novem..	PR

More news

News in other languages on INOVIO PHARMACEUTICALS, INC.

08/11	Wall Street, lestée par la tech, finit dans le rouge
07/01	BioNTech treibt Corona-Impfstoffprojekt nach positiven Daten voran
06/23	WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
06/04	WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
06/03	Coronavirus-Les USA retiennent 5 candidats vaccins, pas Sanofi-NYT

More news

Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.

11/10	Arcturus expects its COVID-19 vaccine to be ready by Q1 2021	RE
02/05	Drugmakers see long road ahead in coronavirus vaccine race	RE

More recommendations

Stock Trading Strategies

	INOVIO PHARMACEUTICALS, INC. - 05/22
Close to a key resistance level

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Analysis

Inovio Pharmaceuticals : Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses